- Negotiations with Biontech and Pfizer on vaccine supply contracts have ended on Wednesday.
- EU Health Commissioner Stella Kyriakides hopes to formulate a package of regulations to enable the EU to better prevent future pandemics.
- Some people worry that the vaccine developed in cooperation with Pfizer in the United States may initially be first promoted in the United States.
The European Union has reached a 300 million dose vaccine supply agreement with biotech companies, Biontech and Pfizer. Biontech emphasized that vaccines will be distributed fairly. At the same time, Germany is considering how to specifically implement the new coronavirus vaccine.
European Commission President Ursula von der Leyen announced on Tuesday that negotiations with the German biotech company Biontech and the US Pfizer pharmaceutical company on vaccine supply contracts have ended on Wednesday.
In addition, EU Health Commissioner Stella Kyriakides hopes to formulate a package of regulations to enable the EU to better prevent future pandemics and similar risks. Ursula von der Leyen said:
“In the wake of Monday’s promising announcement by BioNTech and Pfizer on the prospects for their vaccine, I’m very happy to announce today’s agreement with the European company BioNTech and Pfizer to purchase 300 million doses of the vaccine. With this fourth contract we are now consolidating an extremely solid vaccine candidate portfolio, most of them in advanced trials phase. Once authorized, they will be quickly deployed and bring us closer to a sustainable solution of the pandemic.”
Biontech and Pfizer also announced on Monday that their vaccines are more than 90% effective against the new coronavirus. However, the relevant research has not yet been completed. The two companies announced that they will apply for marketing authorization in the United States as soon as next week and will also apply in Europe. The EU and the two companies reached an agreement to purchase up to 300 million doses of vaccine.
Commissioner Kyriakides said:
“A safe and effective vaccine is the only lasting exit strategy from the pandemic, and is at the center of our European Vaccine Strategy. Today’s agreement follows the encouraging first indications from the clinical trial results and is further evidence of our commitment to putting more Europe in the area of health. It is a very telling example of what the EU can achieve when working together, as a Union, and a case in point of what a future European Health Union will be able to deliver.”
Vaccines will be Distributed Fairly
Some people worry that the vaccine, developed in cooperation with Pfizer in the United States, may initially be first promoted in the United States.
Mainz biotechnology company Biontech dispelled this worry. The company’s chief financial officer, Sionk Poetting, told the Stuttgart News, “we have reached an agreement with Pfizer to distribute vaccines fairly.”
Poetting emphasized that his company “never hopes that there will be unfairness in individual regions where the volume is high.”
This is why Biontech is very focused on being able to produce a large part of the vaccine in Europe. The chief financial officer of the company emphasized, “we will decide the distribution method together with Pfizer.”
Germany is also considering how to implement vaccination. Federal Minister of Health Jens Spahn predicts that Germany will have access to as many as 100 million vaccines developed by Biontech and Pfizer.
The Federal Minister of Scientific Research, Anja Karliczek, said that information and popular science propaganda about vaccination should be carried out. She told reporters from the report that in order to dispel people’s worries about vaccination and its side effects, the federal government will fully ensure transparency.
“In order to eliminate this fear, it is important to provide long-term information to the public and introduce the effectiveness of vaccines and their risks.” Karliczek emphasized that there will be no mandatory vaccination obligations.